S&P 500
(0.32%) 5 116.17 points
Dow Jones
(0.38%) 38 386 points
Nasdaq
(0.35%) 15 983 points
Oil
(-1.34%) $82.73
Gas
(6.55%) $2.05
Gold
(0.01%) $2 347.50
Silver
(-0.35%) $27.44
Platinum
(4.11%) $960.00
USD/EUR
(-0.22%) $0.933
USD/NOK
(-0.34%) $10.99
USD/GBP
(-0.54%) $0.796
USD/RUB
(1.55%) $93.30

Sanntidsoppdatering for Aarti Drugs Limited [AARTIDRUGS.NS]

Børs: NSE Sektor: Healthcare Industri: Drug Manufacturers—Specialty & Generic
Upcoming Earnings Alert

Quarter results today
(bmo 2024-04-29)

Expected move: +/- 4.04%

Sist oppdatert29 apr 2024 @ 11:59

0.58% INR 507.05

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...

Stats
Dagens volum 122 635
Gjennomsnittsvolum 217 350
Markedsverdi 46.62B
EPS INR0 ( 2024-04-13 )
Neste inntjeningsdato ( INR0 ) 2024-07-18
Last Dividend INR1.000 ( 2023-02-08 )
Next Dividend INR0 ( N/A )
P/E 25.92
ATR14 INR0.783 (0.15%)

Volum Korrelasjon

Lang: 0.08 (neutral)
Kort: -0.59 (weak negative)
Signal:(47.257) Neutral

Aarti Drugs Limited Korrelasjon

10 Mest positive korrelasjoner
BBL.NS0.955
RBLBANK.NS0.954
AIRAN.NS0.949
PGHH.NS0.944
KELLTONTEC.NS0.94
HPL.NS0.94
PREMEXPLN.NS0.939
SJVN.NS0.938
TWL.NS0.936
POLYCAB.NS0.934
10 Mest negative korrelasjoner
LTGILTBEES.NS-0.947
SINTEX.NS-0.924
RAJRILTD.NS-0.922
BOHRAIND.NS-0.92
RAJVIR.NS-0.911
BGLOBAL.NS-0.906
IRISDOREME.NS-0.906
OMAXE.NS-0.905
JPINFRATEC.NS-0.903
SRPL.NS-0.901

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Aarti Drugs Limited Korrelasjon - Valuta/Råvare

The country flag 0.20
( neutral )
The country flag 0.47
( neutral )
The country flag 0.00
( neutral )
The country flag -0.32
( neutral )
The country flag 0.26
( neutral )
The country flag -0.53
( weak negative )

Aarti Drugs Limited Økonomi

Annual 2022
Omsetning: INR27.16B
Bruttogevinst: INR8.28B (30.47 %)
EPS: INR17.96
FY 2022
Omsetning: INR27.16B
Bruttogevinst: INR8.28B (30.47 %)
EPS: INR17.96
FY 2022
Omsetning: INR24.89B
Bruttogevinst: INR5.04B (20.24 %)
EPS: INR22.12
FY 2021
Omsetning: INR21.55B
Bruttogevinst: INR6.00B (27.86 %)
EPS: INR30.09

Financial Reports:

No articles found.

Aarti Drugs Limited Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
INR0
(N/A)
INR0
(N/A)
INR1.000
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)
INR0
(N/A)

Aarti Drugs Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.77 - low (58.39%) | Divividend Growth Potential Score: 3.36 - Decrease likely (32.90%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend INR0.150 2003-11-13
Last Dividend INR1.000 2023-02-08
Next Dividend INR0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 32 --
Total Paid Out INR15.88 --
Avg. Dividend % Per Year 0.23% --
Score 2.13 --
Div. Sustainability Score 4.77
Div.Growth Potential Score 3.36
Div. Directional Score 4.06 --
Next Divdend (Est)
(2024-10-31)
INR0 Estimate 0.00 %
Dividend Stability
0.08 Very Bad
Dividend Score
2.13
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2003 INR0 0.00%
2004 INR0 0.00%
2005 INR0 0.00%
2006 INR0 0.00%
2007 INR0 0.00%
2008 INR0 0.00%
2009 INR0 0.00%
2010 INR0 0.00%
2011 INR0 0.00%
2012 INR0 0.00%
2013 INR0 0.00%
2014 INR0 0.00%
2015 INR0 0.00%
2016 INR0 0.00%
2017 INR0 0.00%
2018 INR0.250 0.18%
2019 INR0.250 0.17%
2020 INR3.00 2.03%
2021 INR0 0.00%
2022 INR1.000 0.18%
2023 INR1.000 0.22%
2024 INR0 0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
ROUTE.NS Dividend Junior 2023-09-06 Semi-Annually 4 0.38%
LICHSGFIN.NS Dividend Junior 2023-08-18 Annually 23 1.85%
GANDHITUBE.NS Dividend Junior 2023-07-28 Annually 17 1.82%
APOLSINHOT.NS Dividend Junior 2023-09-22 Annually 10 0.11%
TDPOWERSYS.NS Dividend Junior 2023-08-02 Annually 13 0.31%
OLECTRA.NS Dividend Junior 2023-09-21 Sporadic 23 0.03%
INTENTECH.NS Dividend Junior 2023-09-21 Annually 6 0.44%
COROMANDEL.NS Dividend Knight 2023-07-13 Annually 19 1.02%
SHALBY.NS Dividend Junior 2023-08-08 Annually 6 0.51%
MANALIPETC.NS Dividend Junior 2023-09-15 Annually 18 1.50%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06801.5008.6410.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.1501.5009.4410.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM8.411.0008.008.00[3 - 30]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
freeCashFlowPerShareTTM10.962.004.529.04[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.3221.0007.967.96[0.2 - 0.8]
operatingProfitMarginTTM0.1051.0009.919.91[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score4.77

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM25.921.0007.480[1 - 100]
returnOnEquityTTM0.1502.509.6410.00[0.1 - 1.5]
freeCashFlowPerShareTTM10.962.006.359.04[0 - 30]
dividendYielPercentageTTM0.1971.5005.080[0 - 0.4]
operatingCashFlowPerShareTTM10.962.006.3510.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.3731.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.03801.000-1.5500[0.1 - 0.5]
Total Score3.36

Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.